UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
   Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934

            Date of Report (Date of earliest reported): June 6, 2005

                      ADVANCED PLANT PHARMACEUTICALS, INC.
               (Exact name of registrant as specified in charter)

                          Delaware 000-28459 59-2762023
             (State or other jurisdiction (Commission (IRS Employer
               of incorporation) File Number) Identification No.)


43 West 33rd Street, New York, New York                             10001
(Address of principal executive offices)                         (Zip Code)

        Registrant's telephone number, including area code: 212-695-3334

                                   Copies to:
                             Gregory Sichenzia, Esq.
                            Stephen M. Fleming, Esq.
                       Sichenzia Ross Friedman Ference LLP
                           1065 Avenue of the Americas
                            New York, New York 10018
                              Phone: (212) 930-9700
                               Fax: (212) 930-9725

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[_]   Written  communications  pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

[_]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

[_]   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

[_]   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))

<PAGE>



Item 1.01 Entry into a Material Definitive Agreement.
Item 2.01 Completion of Acquisition or Disposition of Assets

On June 6, 2005, Advanced Plant  Pharmaceuticals,  Inc., a Delaware  corporation
(the  "Registrant"),  consummated  the  transactions  contemplated  by the Share
Exchange Agreement dated as of May 2005 (the "Share Exchange  Agreement") by and
among the Registrant,  Akid Corporation ("Akid") and James B. Wiegand.  Pursuant
to the Share  Exchange  Agreement,  the  Registrant  sold its  entire  ownership
interest in 7,000,000  shares of the common stock of Mazal Plant  Pharmaceutical
Inc., a Delaware  corporation  ("Mazal"),  to Akid. In exchange,  Akid agreed to
issue to the  Registrant  20,000,000  shares (the  "Exchange  Shares") of Akid's
common stock.  Following the consummation of such share exchange, the Registrant
holds a majority of the issued and  outstanding  common shares of Akid, and Akid
holds a majority of the issued and outstanding common shares of Mazal.

Akid issued to the Registrant  17,500,000 of the Exchange Shares at the closing,
and  agreed  to issue  the  remaining  2,500,000  of the  Exchange  Shares  upon
increasing  its  authorized  common stock from  20,000,000  shares to 40,000,000
shares.

Registrant  will file an  amendment  to this  Current  Report on Form 8-K.  This
amendment will include the requisite  financial  information  regarding Akid and
the pro forma  financials as a result of Registrant's  acquisition of a majority
interest in Akid.

Item 9.01 Financial Statements and Exhibits

(a)   Financial Statements of business acquired.

      Audited Financial  Statements of Akid for the year ended December 31, 2004
      Unaudited  Financial  Statements  of Akid for the three months ended March
      31, 2005

(b)   Pro forma financial information.

      Pro Form Financial Statements of the Registrant and Akid

(c)   Exhibits

Exhibit No.                Description

10.1              Share Exchange Agreement, dated May 2005, among Akid
                  Corporation, the Registrant and James B. Wiegand.



<PAGE>


                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                        ADVANCED PLANT PHARMACEUTICALS, INC.



Date:  July 14, 2005                    /s/David Lieberman
                                        --------------------------
                                        David Lieberman
                                        Chief Executive Officer
{"company-data": {"conformed-name": "ADVANCED PLANT PHARMACEUTICALS INC", "cik": "0000943535", "assigned-sic": "2020", "irs-number": "592762023", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-30256", "film-number": "05954025"}, "business-address": {"street1": "43 W 33RD STREET", "city": "NEW YORK", "state": "NY", "zip": "10001", "phone": "2124027878"}, "mail-address": {"street1": "43 W 33RD STREET", "city": "NEW YORK", "state": "NY", "zip": "10001"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
   Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934

            Date of Report (Date of earliest reported): June 6, 2005

                      ADVANCED PLANT PHARMACEUTICALS, INC.
               (Exact name of registrant as specified in charter)

                          Delaware 000-28459 59-2762023
             (State or other jurisdiction (Commission (IRS Employer
               of incorporation) File Number) Identification No.)

43 West 33rd Street, New York, New York                             10001
(Address of principal executive offices)                         (Zip Code)

        Registrant's telephone number, including area code: 212-695-3334

                                   Copies to:
                             Gregory Sichenzia, Esq.
                            Stephen M. Fleming, Esq.
                       Sichenzia Ross Friedman Ference LLP
                           1065 Avenue of the Americas
                            New York, New York 10018
                              Phone: (212) 930-9700
                               Fax: (212) 930-9725

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[_]   Written  communications  pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

[_]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

[_]   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

[_]   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
Item 2.01 Completion of Acquisition or Disposition of Assets

On June 6, 2005, Advanced Plant  Pharmaceuticals,  Inc., a Delaware  corporation
(the  "Registrant"),  consummated  the  transactions  contemplated  by the Share
Exchange Agreement dated as of May 2005 (the "Share Exchange  Agreement") by and
among the Registrant,  Akid Corporation ("Akid") and James B. Wiegand.  Pursuant
to the Share  Exchange  Agreement,  the  Registrant  sold its  entire  ownership
interest in 7,000,000  shares of the common stock of Mazal Plant  Pharmaceutical
Inc., a Delaware  corporation  ("Mazal"),  to Akid. In exchange,  Akid agreed to
issue to the  Registrant  20,000,000  shares (the  "Exchange  Shares") of Akid's
common stock.  Following the consummation of such share exchange, the Registrant
holds a majority of the issued and  outstanding  common shares of Akid, and Akid
holds a majority of the issued and outstanding common shares of Mazal.

Akid issued to the Registrant  17,500,000 of the Exchange Shares at the closing,
and  agreed  to issue  the  remaining  2,500,000  of the  Exchange  Shares  upon
increasing  its  authorized  common stock from  20,000,000  shares to 40,000,000
shares.

Registrant  will file an  amendment  to this  Current  Report on Form 8-K.  This
amendment will include the requisite  financial  information  regarding Akid and
the pro forma  financials as a result of Registrant's  acquisition of a majority
interest in Akid.

Item 9.01 Financial Statements and Exhibits

(a)   Financial Statements of business acquired.

      Audited Financial  Statements of Akid for the year ended December 31, 2004
      Unaudited  Financial  Statements  of Akid for the three months ended March
      31, 2005

(b)   Pro forma financial information.

      Pro Form Financial Statements of the Registrant and Akid

(c)   Exhibits

Exhibit No.                Description

10.1              Share Exchange Agreement, dated May 2005, among Akid
                  Corporation, the Registrant and James B. Wiegand.
SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                        ADVANCED PLANT PHARMACEUTICALS, INC.

Date:  July 14, 2005                    /s/David Lieberman
                                        --------------------------
                                        David Lieberman
                                        Chief Executive Officer